FDA Updates Depo-Provera Label to Include Brain Tumor Risk — Key Litigation Development

The label revision follows emerging evidence linking long-term use of Depo-Provera (medroxyprogesterone acetate) to a higher likelihood of developing meningiomas — tumors that, while often benign, can cause serious neurological effects such as seizures, vision impairment, and headaches. Studies have suggested that women who use Depo-Provera for extended periods may face a significantly increased risk of these tumors compared with users of other contraceptives.

Regulatory and Litigation Context

The FDA’s action comes amid a growing body of litigation alleging that the drug’s manufacturer, Pfizer, did not adequately warn patients and healthcare providers about this risk. For months, plaintiffs in multidistrict litigation (MDL) and state court actions had pointed to scientific studies and international regulatory changes as evidence of a known risk that was not reflected on U.S. labeling. Many lawsuits argue that similar warnings exist on Depo-Provera products sold in Canada and Europe, but were absent from U.S. labels until now.

In the ongoing federal MDL centralized before Judge M. Casey Rodgers in the Northern District of Florida, plaintiffs have alleged failure-to-warn and design defect claims against Pfizer and other manufacturers. As of early December 2025, thousands of claims have been consolidated, with case counts in the MDL climbing steadily over the past year.

One of the central legal questions has been whether the FDA’s prior rejection of a proposed label change, made by Pfizer in 2023, preempts state-law failure-to-warn claims. The company previously submitted labeling language to the agency that the FDA did not approve, and courts have been weighing whether that regulatory history affects plaintiffs’ ability to proceed with their claims.

What the Label Change Means

The FDA’s decision to formally update the Depo-Provera label to include brain tumor risk represents a departure from past U.S. labeling, which primarily focused on other safety concerns such as bone mineral density loss. Under the updated prescribing information, clinicians and patients will now see explicit reference to a potential association with meningioma, consistent with emerging clinical evidence and international regulatory practices.

For healthcare providers and patients, this update aims to enhance informed decision-making by ensuring that all known safety information is clearly communicated. For plaintiffs and counsel involved in the Depo-Provera litigation, the label change is likely to influence litigation strategy and evidentiary discussions — even though the litigation itself has advanced significantly over the past year.

Next Steps in Litigation

With the MDL now containing well over a thousand individual claims alleging neurological harm, the litigation continues to evolve as courts address dispositive motions, case management schedules, and preparations for bellwether trials. A ruling on federal preemption and other key legal defenses could shape how many of these cases proceed.

As the litigation and regulatory landscapes evolve, this label change signals increased scrutiny of Depo-Provera’s risk profile and highlights the growing intersection of drug safety oversight and mass tort litigation.

The Food and Drug Administration approved on Friday a label change for Pfizer's birth control shot Depo-Provera that warns patients of the risk of meningioma, a tumor in the lining of the brain. Pfizer is currently battling a lawsuit in which more than 1,000 women claim the company knew about the risk and failed to warn patients.

[View source.]